Possible involvement of sphingomyelin in the regulation of the plasma sphingosine 1-phosphate level in human subjects.

[1]  Sarah Spiegel,et al.  Export of sphingosine-1-phosphate and cancer progression , 2014, Journal of Lipid Research.

[2]  K. Tsuneyama,et al.  Induction of insulin secretion by apolipoprotein M, a carrier for sphingosine 1-phosphate. , 2014, Biochimica et biophysica acta.

[3]  Anne-Kathrin Kienzler,et al.  Sphingosine-1-phosphate receptors control B-cell migration through signaling components associated with primary immunodeficiencies, chronic lymphocytic leukemia, and multiple sclerosis. , 2014, The Journal of allergy and clinical immunology.

[4]  Y. Yatomi,et al.  TNF-&agr; production in NKT cell hybridoma is regulated by sphingosine-1-phosphate: implications for inflammation in atherosclerosis , 2014, Coronary artery disease.

[5]  N. Hemdan,et al.  Sphingosine 1-Phosphate in Blood: Function, Metabolism, and Fate , 2014, Cellular Physiology and Biochemistry.

[6]  R. Erbel,et al.  HDL-Bound Sphingosine 1-Phosphate (S1P) Predicts the Severity of Coronary Artery Atherosclerosis , 2014, Cellular Physiology and Biochemistry.

[7]  M. Kurano,et al.  Modulation of sphingosine-1-phosphate and apolipoprotein M levels in the plasma, liver and kidneys in streptozotocin-induced diabetic mice , 2014, Journal of diabetes investigation.

[8]  K. Tsuchiya,et al.  Sphingosine‐1‐phosphate acts as a key molecule in the direct mediation of renal fibrosis , 2013, Physiological reports.

[9]  B. Sobel,et al.  Increased plasma sphingosine-1-phosphate in obese individuals and its capacity to increase the expression of plasminogen activator inhibitor-1 in adipocytes , 2013, Coronary artery disease.

[10]  M. Kurano,et al.  Liver involvement in sphingosine 1-phosphate dynamism revealed by adenoviral hepatic overexpression of apolipoprotein M. , 2013, Atherosclerosis.

[11]  M. Kurano,et al.  Sphingosine 1-phosphate release from platelets during clot formation: close correlation between platelet count and serum sphingosine 1-phosphate concentration , 2013, Lipids in Health and Disease.

[12]  N. Hayashi,et al.  Development of an enzymatic assay for sphingomyelin with rapid and automatable performances: Analysis in healthy subjects and coronary heart disease patients. , 2012, Clinical biochemistry.

[13]  B. Dahlbäck,et al.  Endothelium-protective sphingosine-1-phosphate provided by HDL-associated apolipoprotein M , 2011, Proceedings of the National Academy of Sciences.

[14]  Y. Inoue,et al.  Plasma concentration of bioactive lipid mediator sphingosine 1-phosphate is reduced in patients with chronic hepatitis C. , 2010, Clinica chimica acta; international journal of clinical chemistry.

[15]  A. Lisowska,et al.  Plasma sphingosine-1-phosphate concentration is reduced in patients with myocardial infarction. , 2009, Medical science monitor : international medical journal of experimental and clinical research.

[16]  H. Ikeda,et al.  Plasma sphingosine-1-phosphate measurement in healthy subjects: close correlation with red blood cell parameters , 2008, Annals of clinical biochemistry.

[17]  H. Bonkovsky,et al.  Vascular Endothelium As a Contributor of Plasma Sphingosine 1-Phosphate , 2008, Circulation research.

[18]  M. Nangaku,et al.  Validation of an autotaxin enzyme immunoassay in human serum samples and its application to hypoalbuminemia differentiation. , 2008, Clinica chimica acta; international journal of clinical chemistry.

[19]  J. Cyster,et al.  Promotion of Lymphocyte Egress into Blood and Lymph by Distinct Sources of Sphingosine-1-Phosphate , 2007, Science.

[20]  Y. Kishi,et al.  Autotaxin Stabilizes Blood Vessels and Is Required for Embryonic Vasculature by Producing Lysophosphatidic Acid* , 2006, Journal of Biological Chemistry.

[21]  J. Nelson,et al.  Plasma sphingomyelin and subclinical atherosclerosis: findings from the multi-ethnic study of atherosclerosis. , 2006, American journal of epidemiology.

[22]  H. Matsuyuki,et al.  Role of sphingosine 1-phosphate receptor type 1 in lymphocyte egress from secondary lymphoid tissues and thymus. , 2006, Cellular & molecular immunology.

[23]  Y. Yatomi,et al.  Sphingosine 1-phosphate in vascular biology: possible therapeutic strategies to control vascular diseases. , 2006, Current pharmaceutical design.

[24]  S. Blankenberg,et al.  Further evaluation of plasma sphingomyelin levels as a risk factor for coronary artery disease , 2006, Nutrition & metabolism.

[25]  Hugh Rosen,et al.  Lysophospholipid receptors as potential drug targets in tissue transplantation and autoimmune diseases. , 2006, Current pharmaceutical design.

[26]  J. Cyster,et al.  FTY720: Sphingosine 1‐Phosphate Receptor‐1 in the Control of Lymphocyte Egress and Endothelial Barrier Function , 2004, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[27]  M. Vanier,et al.  Sphingosylphosphorylcholine in Niemann-Pick Disease Brain: Accumulation in Type A But Not in Type B , 1999, Neurochemical Research.

[28]  G. Mills,et al.  Autotaxin hydrolyzes sphingosylphosphorylcholine to produce the regulator of migration, sphingosine-1-phosphate. , 2003, Cancer research.

[29]  Sarah Spiegel,et al.  Sphingosine-1-phosphate: an enigmatic signalling lipid , 2003, Nature Reviews Molecular Cell Biology.

[30]  K. Fukuzawa,et al.  Identification of Human Plasma Lysophospholipase D, a Lysophosphatidic Acid-producing Enzyme, as Autotaxin, a Multifunctional Phosphodiesterase* , 2002, The Journal of Biological Chemistry.

[31]  G. Mills,et al.  Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production , 2002, The Journal of cell biology.

[32]  Y. Soda,et al.  An enzymatic assay for lysophosphatidylcholine concentration in human serum and plasma. , 2002, Clinical biochemistry.

[33]  M. Macey,et al.  Evaluation of the anticoagulants EDTA and citrate, theophylline, adenosine, and dipyridamole (CTAD) for assessing platelet activation on the ADVIA 120 hematology system. , 2002, Clinical chemistry.

[34]  P. Valet,et al.  Secretion of a lysophospholipase D activity by adipocytes: involvement in lysophosphatidic acid synthesis. , 2002, Journal of lipid research.

[35]  T. Hla,et al.  Signaling of sphingosine-1-phosphate via the S1P/EDG-family of G-protein-coupled receptors. , 2002, Biochimica et biophysica acta.

[36]  T. Ohmori,et al.  Sphingosine 1-phosphate: synthesis and release. , 2001, Prostaglandins & other lipid mediators.

[37]  L. Pott,et al.  Sphingosylphosphocholine is a naturally occurring lipid mediator in blood plasma: a possible role in regulating cardiac function via sphingolipid receptors. , 2001, The Biochemical journal.

[38]  A. Tall,et al.  Plasma Sphingomyelin Level as a Risk Factor for Coronary Artery Disease , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[39]  J. P. Hobson,et al.  Edg-1, the G protein-coupled receptor for sphingosine-1-phosphate, is essential for vascular maturation. , 2000, The Journal of clinical investigation.

[40]  G. Imokawa,et al.  High-expression of sphingomyelin deacylase is an important determinant of ceramide deficiency leading to barrier disruption in atopic dermatitis. , 2000, The Journal of investigative dermatology.

[41]  Y. Igarashi,et al.  Sphingosine 1-Phosphate Induces Platelet Activation through an Extracellular Action and Shares a Platelet Surface Receptor with Lysophosphatidic Acid* , 1997, The Journal of Biological Chemistry.

[42]  S. Zeisel,et al.  Choline, phosphatidylcholine and sphingomyelin in human and bovine milk and infant formulas. , 1986, The Journal of nutrition.

[43]  M. Takayama,et al.  A new enzymatic method for determination of serum choline-containing phospholipids. , 1977, Clinica chimica acta; international journal of clinical chemistry.